U.S. Markets open in 5 hrs 31 mins

INmune Bio, Inc. (INMB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.89-0.60 (-5.72%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.49
Open10.49
Bid0.00 x 800
Ask0.00 x 800
Day's Range9.89 - 10.77
52 Week Range2.20 - 24.42
Volume200,845
Avg. Volume1,036,462
Market Cap133M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.89
Earnings DateAug 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
  • GlobeNewswire

    INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update

    The company will host an earnings call: Today, August 5 at 4:30 PM ETLA JOLLA, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease today reported its financial results for the second quarter ended June 30, 2020 and is providing a business update. INmune Bio will hold a conference call today at 4:30 PM Eastern Time. To participate in the call, please dial 415-226-5355 five minutes before the scheduled time. “In the second quarter, and year to date, INmune Bio continued to progress forward with both of our clinical platforms,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “We announced interim Phase Ib data demonstrating that our Alzheimer’s Disease candidate, XPro1595, can reduce neuroinflammation. Our progress with XPro1595 supports our overall strategy to create platforms of therapeutics, based on reducing inflammation by targeting the innate immune system to fight disease.  We are planning a number of programs employing this approach in NASH, MUC4 expressing HER2+ cancer, ALS and complications of cytokine storm caused by COVID-19.  With the Natural Killer Priming platform, we anticipate INKmune™ Phase I in high-risk MDS to start the second half of this year.”Q2 2020 and Recent Corporate Highlights DN-TNF Platform Highlights: * Announced interim Phase Ib data demonstrating that XPro1595 decreases neuroinflammation in patients with Alzheimer's Disease - XPro1595 reduced neuroinflammation by 40.6% in a white matter tract important for learning and memory. * Announced combination therapy of Lapatinib with INB03 may be used to overcome resistance to trastuzumab in women with MUC4+/HER2+ breast cancer.  This work was presented at the AACR 2020 by Dr. Roxana Schillaci and may form the basis for a Phase II program in patients with MUC4 expressing HER2+ cancer. * Initiated a clinical program to test targeting soluble TNF (Quellor™), one of the key components of the cytokine storm, using our TNF Inhibitor (DN-TNF) Platform to prevent complications of COVID-19 infection.  * Frontiers in Oncology published an invited entitled Tumor Necrosis Factor α Blockade: an Opportunity to Tackle Breast Cancer by Prof. Roxana Schillaci, a leader in the field of TNF in cancer.NK Priming Platform Highlights: * Received regulatory clearance from UK MHRA to initiate a Phase I Trial of INKmune in patients with high-risk MDS - study will be the first-in man trial for INKmune – a novel therapy to prime the patient’s own NK cells to attack their cancer. * Announced allowance of U.S. Patent covering method for treating cancer by in-vivo priming of natural killer cells. * Received notice of allowance in counterpart patent in Australia covering method for treating cancer by in-vivo priming of natural killer cells. * Announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by Prof. Mark Lowdell, Co-Founder and CSO of INmune Bio, Inc.  The article reviews the potential of harnessing cells of the innate immune system to treat cancer.Financial Highlights: * Closed a $25 million gross proceeds public offering of common stock, including full exercise of Underwriters’ Over-Allotment Option resulting in net proceeds of approximately $23.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.Upcoming Milestones: * Report additional data on Phase 1b XPro1595 in Alzheimer’s Disease in 2H 2020. * Enroll first patient in Phase II Quellor™ program, targeting COVID-19 patients with immune mediated complications from COVID-19. * Enroll first patient in Phase I INKmune™ in High Risk MDS cancer, expected 2H20. * Enroll first patient in Phase I INKmune™ in Ovarian cancer, expected mid-2021.Financial Results for the Second Quarter Ended June 30, 2020:Net loss attributable to common stockholders for the second quarter ended June 30, 2020 was $2.1 million, compared to $0.4 million for the quarter ended June 30, 2019.Research and development expense totaled approximately $0.9 million for the second quarter ended June 30, 2020, compared to approximately $0.6 million during the second quarter ended June 30, 2019.General and administrative expense was approximately $1.2 million for the quarter ended June 30, 2020, compared to approximately $1.3 million during the second quarter ended June 30, 2019.As of June 30, 2020, the Company had cash and cash equivalents of approximately $4.8 million with no debt. Subsequent to the quarter end, INmune Bio closed a $25 million gross proceeds public offering of common stock resulting in net proceeds of approximately $23.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.As of August 5, 2020, the Company had approximately 13.4 million common shares outstanding.Earnings Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date: August 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 1-415-226-5355About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Information about Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact:  James Carbonara (646) 755-7412 James@haydenir.comThe following table summarizes our results of operations for the periods indicated:INMUNE BIO, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2020  December 31, 2019         ASSETS        CURRENT ASSETS        Cash and cash equivalents$4,816,561  $6,995,525  Research and development tax credit receivable 1,044,843   568,139  Other tax receivable 155,000   77,225  Prepaid expenses 342,492   97,623  Prepaid expenses – related party -   26,266           TOTAL CURRENT ASSETS 6,358,896   7,764,778           Operating lease – right of use asset – related party 174,649   191,543  Acquired in-process research and development intangible assets 16,514,000   16,514,000           TOTAL ASSETS$23,047,545  $24,470,321           LIABILITIES AND STOCKHOLDERS’ EQUITY                 CURRENT LIABILITIES        Accounts payable and accrued liabilities$624,893  $401,989  Accounts payable and accrued liabilities – related parties 223,562   290,102  Deferred liabilities 361,842   -  Operating lease, current liability – related party 6,950   8,288  TOTAL CURRENT LIABILITIES 1,217,247   700,379           Long-term operating lease liability – related party 145,430   160,164  TOTAL LIABILITIES 1,362,677   860,543           COMMITMENTS AND CONTINGENCIES                 STOCKHOLDERS’ EQUITY        Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding -   -  Common stock, $0.001 par value, 200,000,000 shares authorized, 10,897,630 and 10,770,948 shares issued and outstanding, respectively 10,898   10,771  Additional paid-in capital 47,068,236   44,833,703  Common stock issuable 50,000   50,000  Accumulated other comprehensive loss 10,126   (8,515) Accumulated deficit (25,454,392)  (21,276,181) TOTAL STOCKHOLDERS' EQUITY 21,684,868   23,609,778           TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$23,047,545  $24,470,321            INMUNE BIO, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the Three Months Ended June 30,  For the Six Months Ended June 30,   2020  2019  2020  2019  REVENUE$-  $-  $-  $-                   OPERATING EXPENSES                General and administrative 1,204,366   1,335,727   2,503,840   2,634,106  Research and development 903,043   634,696   1,695,830   1,247,404  Waiver of common stock issuable -   (1,542,000)  -   (1,542,000) Total operating expenses 2,107,409   428,423   4,199,670   2,339,510                   LOSS FROM OPERATIONS (2,107,409)  (428,423)  (4,199,670)  (2,339.510)                  OTHER (EXPENSE) INCOME (395)  36,340   21,459   46,382                   NET LOSS$(2,107,804) $(392,083) $(4,178,211) $(2,293,128)                  Net loss per common share – basic and diluted$(0.20) $(0.04) $(0.39) $(0.23)                  Weighted average common shares outstanding - basic and diluted 10,800,708   10,150,810   10,774,004   9,771,833                   COMPREHENSIVE LOSS                Net loss$(2,107,804) $(392,083) $(4,178,211) $(2,293,128) Other comprehensive gain (loss) – gain (loss) on foreign currency translation 39,378   (25,014)  18,641   (25,736)                  Total comprehensive loss$(2,068,426) $(417,097) $(4,159,570) $(2,318,864)                  INMUNE BIO, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the Six Months Ended June 30,   2020  2019  CASH FLOWS FROM OPERATING ACTIVITIES:        Net loss$(4,178,211) $(2,293,128) Adjustments to reconcile net loss to net cash used in operating activities:        Stock-based compensation 1,363,410   1,949,395  Waiver of common stock issuable -   (1,542,000) Changes in operating assets and liabilities:        Research and development tax credit receivable (476,704)  (251,472) Other tax receivable (77,775)  (67,315) Joint development cost receivable -   (31,340) Prepaid expenses (244,869)  (184,472) Prepaid expenses – related party 26,266   (244,882) Accounts payable and accrued liabilities 222,904   (115,004) Accounts payable and accrued liabilities – related parties 149,221   (200,654) Deferred liabilities 361,842   -  Operating lease liability – related party 822   (24,653) Net cash used in operating activities (2,853,094)  (3,005,525)          CASH FLOWS FROM FINANCING ACTIVITIES:        Net proceeds from sale of common stock 1,667,489   12,209,021  Purchase of common stock (1,012,000)  -  Net cash provided by financing activities 655,489   12,209,021           Impact on cash from foreign currency translation 18,641   (25,736)          NET (DECREASE) INCREASE IN CASH (2,178,964)  9,177,760           CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 6,995,525   186,204           CASH AND CASH EQUIVALENTS AT END OF PERIOD$4,816,561  $9,363,964           SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:        Cash paid for income taxes$-  $-  Cash paid for interest expense$-  $-           NONCASH INVESTING AND FINANCING ACTIVITIES:        Capital contribution$215,761  $-  Issuance of warrants to placement agents$-  $247,452  Issuance of common stock issuable$-  $3,084,000

  • GlobeNewswire

    INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020

    LA JOLLA, Calif, Aug. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that management will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference being held August 10-11, 2020 and will also be available for 1x1 meetings. To schedule a meeting, please contact your BTIG representative or email James@HaydenIR.com.       INmune Bio Fireside Chat Details:BTIG Virtual Biotechnology Conference 2020 Date:  Monday, August 10, 2020 Presentation Time:  1:00 - 1:25 PM ETAbout INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including without limitation statements regarding the completion and timing of the offering and the amount and use of proceeds therefrom, are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.      INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: James Carbonara, Hayden IR (646) 755-7412 james@haydenir.com

  • GlobeNewswire

    INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results

    LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on August 5, 2020 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2020. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator.Date: August 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 212-231-2931A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available for approximately one week by calling 412-317-6671 and entering PIN no. 21967252.About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including without limitation statements regarding the completion and timing of the offering and the amount and use of proceeds therefrom, are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate™, Quellor™ and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact:  David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: James Carbonara, Hayden IR (646) 755-7412 james@haydenir.com